ectopic expression of hsa-mir-182 significantly inhibits lung cancer cell proliferation and anchorage-independent cell growth, which can be rescued by re-expression of RGS17.

Endogenous mature miR-182 expression may have an important role in the pathogenesis of lung cancer through its interference with the target gene CTTN by epigenetic modification.

Downregulation of microRNA-182 inhibits cell growth and invasion by targeting programmed cell death 4 in human lung adenocarcinoma cells.

In the early stages of lung cancer progression, Sp1 stimulates miR-182 expression, which in turn decreases FOXO3 expression.

The results of the present study demonstrated that overexpression of miR-182 may be involved in chemoresistance of non-small cell lung cancer cells to cisplatin by down-regulating PDCD4.

The miR-200 family and the miR-183~96 and mir-182 cluster target Foxf2 to inhibit invasion and metastasis in lung cancers.

High miR182 expression is associated with lung tumorigenesis.

MiR-182-5p upregulation is associated with lung squamous cell carcinoma.

MiR-182 promotes glucose metabolism by upregulating HIF-1alpha in Non-Small Cell lung cancer cells

our results demonstrated that miR-182 targeted CTTN gene in NSCLC and suppressed lung cancer invadopodia formation, and thus suppressed lung cancer metastasis.

miR-182 might account for radioresistance in lung cancer and that miR-182-FOXO3 provides a novel radiosensitizing target

Both in vivo and in vitro experiments revealed that circCRIM1 suppresses the invasion and metastasis of lung adenocarcinoma (LUAC) by promoting the expression of leukemia inhibitory factor receptor, a well-known tumor suppressor, by sponging miR-93 and miR-182. In the clinical and pathological analyses, the downregulation of circCRIM1 in LUAC was significantly correlated with lymphatic metastasis and TNM stage.

Our results indicate that the miR-182-5p/GLI2 axis modulates tumorigenesis and cisplatin-resistance in lung adenocarcinoma (LADC) cells, by influencing the hedgehog signaling pathway (HHSP). Therefore, this axis might be considered as a potential biomarker and future therapeutic target in LADC patients

Hsa_circ_0002483 inhibited the progression and enhanced the Taxol sensitivity of non-small cell lung cancer by targeting miR-182-5p.

MiR-182-5p and its target HOXA9 in non-small cell lung cancer: a clinical and in-silico exploration with the combination of RT-qPCR, miRNA-seq and miRNA-chip.